Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start by CNBC Markets | February 12, 2026 2:05 am | US Markets The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
